BBIO

BridgeBioB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment AI

B+

Bull case

20%

Probability

Target price

$115.50

Analysis reference price unavailable

Analysis 2026-01-19 · RankAlpha Sentiment AI

Most likely

Base case

60%

Probability

Target price

$85.79

Analysis reference price unavailable

Analysis 2026-01-19 · RankAlpha Sentiment AI

B-

Bear case

20%

Probability

Target price

$42.63

Analysis reference price unavailable

Analysis 2026-01-19 · RankAlpha Sentiment AI

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-01-19

AI commentary

Sentiment is cautiously constructive: analyst median sits in the mid-$80s while highs/lows are dispersed, reflecting binary clinical risk. Near-term volatility likely around corporate updates and readouts.

RankAlpha Sentiment AI - 2026-01-19

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-04-19catalystQuarterly results & analyst updatesHigh impact

Quarterly report and ensuing analyst revisions could reset guidance; consensus band reflects binary program outcomes.

2026-07-18eventClinical readouts (lead programs)High impact

Interim or pivotal readouts from lead programs may produce large directional moves; date set conservatively to the disclosed window end.

2027-01-19catalystRegulatory, partnering & financing developmentsHigh impact

Regulatory decisions, partnerships, or financing events over 12 months can meaningfully re-rate valuation; analyst dispersion highlights optionality risk/reward.

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-01-19 • Updated nightlySource: Internal modelMethodology